Recent Updates
Recently added Catalysts
NVO Positive Sentiment

Orbis Medicines Enters Multi-Target Drug Discovery Partnership with Novo Nordisk Worth up to USD 1.4 Billion

Thursday, September 17, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Orbis Medicines has entered a strategic partnership with Novo Nordisk to develop oral macrocycle therapeutics targeting cardiometabolic diseases. This collaboration allows for the acceleration of creating a new class of medicines. The agreement could yield up to USD 1.4 billion, reflecting significant investment in innovative therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Strategic collaboration with Novo Nordisk enhances drug discovery capabilities.
  • Potential for developing next-generation oral macrocycle therapeutics.
  • Agreement worth up to USD 1.4 billion indicates strong market confidence.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
2.9%
average across 15 past catalysts
Lead asset
IDegLira
Phase 3 · Diabetes Mellitus

Full Press Release Details

COPENHAGEN, Denmark--(BUSINESS WIRE)--Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a strategic collaboration and license agreement with Novo Nordisk to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases. The agreement enables the acceleration of the development of a new class of orally available medicines for high-value therapeutic targets. Under the terms of the agreement, Orbis Medicines is eligible to receive up to U

Frequently Asked Questions

What is the focus of the Orbis and Novo Nordisk partnership?

The partnership focuses on discovering and developing oral macrocycle therapeutics for cardiometabolic diseases.

How much is the agreement between Orbis and Novo Nordisk worth?

The agreement is worth up to USD 1.4 billion.

What type of medicines are being developed in this collaboration?

The collaboration aims to develop next-generation oral macrocycle medicines.

Where is Orbis Medicines based?

Orbis Medicines is based in Copenhagen, Denmark.

ShareAdd on Google
Tags: NVO Viatris Investor Conferences Healthcare Orbis Medicines Novo Nordisk drug discovery cardiometabolic diseases oral macrocycle therapeutics
Last updated: Sep 17, 2026

Biotech snapshot

Lead asset
IDegLiraPhase 3
Diabetes Mellitus →

Catalyst track record

+46%
best trade around NVO's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for NVO.

See every catalyst's timing & PoA →